TY - JOUR
T1 - Rodent models for dry eye syndrome
T2 - Standardization using benzalkonium chloride and scopolamine hydrobromide
AU - Chaudhari, Pinal
AU - Satarker, Sairaj
AU - Thomas, Rinu
AU - Theruveethi, Nagarajan
AU - Ghate, Vivek
AU - Nampoothiri, Madhavan
AU - Lewis, Shaila A.
N1 - Funding Information:
This work was supported by the Department of Biotechnology (DBT), Government of India, New Delhi (Grant No. BT/PR26970/NNT/28/1509/2017 ).
Funding Information:
The authors are grateful to the Manipal College of Pharmaceutical Sciences (MCOPS) and Manipal Academy of Higher Education (MAHE) for providing necessary facilities for carrying out the research work. This work was supported by the Department of Biotechnology (DBT), Government of India, New Delhi (Grant No. BT/PR26970/NNT/28/1509/2017).
Publisher Copyright:
© 2023 Elsevier Inc.
PY - 2023/3/15
Y1 - 2023/3/15
N2 - Dry eye disease is a highly prevalent ocular condition that significantly affects the quality of life and presents a major challenge in ophthalmology. Animal models play a crucial role in investigating the pathophysiology and developing effective treatments. The goal of this study was to compare and standardize two dry eye disease rodent models and explore their recovery aspects. We have standardized benzalkonium chloride and scopolamine-induced dry eye disease models which represents two different classes of the dry eye i.e., evaporative dry eye and aqueous deficient dry eye, respectively. After the development of dry eye conditions, a self-recovery period of seven days was granted to assess the reversal of the induced changes. The dry eye condition was assessed by measuring tear volume, corneal slit lamp imaging, and histological examination of the cornea, the lacrimal and the harderian gland. The study indicated the development of chronic inflammation of the cornea and lacrimal gland in the case of benzalkonium after five days of the treatment, while the scopolamine treated group showed chronic inflammation of the lacrimal gland after five days and corneal inflammation after seven days of administration. The recovery study suggested that after discontinuation of inducing agent, the dry eye symptoms were still persistent suggesting the utility of the model in evaluating dry eye treatments. The study highlights the comparative changes in both models along with recovery which can serve as a base for drug discovery and development against dry eye disease.
AB - Dry eye disease is a highly prevalent ocular condition that significantly affects the quality of life and presents a major challenge in ophthalmology. Animal models play a crucial role in investigating the pathophysiology and developing effective treatments. The goal of this study was to compare and standardize two dry eye disease rodent models and explore their recovery aspects. We have standardized benzalkonium chloride and scopolamine-induced dry eye disease models which represents two different classes of the dry eye i.e., evaporative dry eye and aqueous deficient dry eye, respectively. After the development of dry eye conditions, a self-recovery period of seven days was granted to assess the reversal of the induced changes. The dry eye condition was assessed by measuring tear volume, corneal slit lamp imaging, and histological examination of the cornea, the lacrimal and the harderian gland. The study indicated the development of chronic inflammation of the cornea and lacrimal gland in the case of benzalkonium after five days of the treatment, while the scopolamine treated group showed chronic inflammation of the lacrimal gland after five days and corneal inflammation after seven days of administration. The recovery study suggested that after discontinuation of inducing agent, the dry eye symptoms were still persistent suggesting the utility of the model in evaluating dry eye treatments. The study highlights the comparative changes in both models along with recovery which can serve as a base for drug discovery and development against dry eye disease.
UR - http://www.scopus.com/inward/record.url?scp=85147660098&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85147660098&partnerID=8YFLogxK
U2 - 10.1016/j.lfs.2023.121463
DO - 10.1016/j.lfs.2023.121463
M3 - Article
C2 - 36731648
AN - SCOPUS:85147660098
SN - 0024-3205
VL - 317
JO - Life Sciences
JF - Life Sciences
M1 - 121463
ER -